62. Paroxysmal nocturnal hemoglobinuria Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108
Drugs and their primary sponsors and trial info
ABP 959
Amgen
2019 Phase 3 NCT03818607 Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
ABP 959 - biosimilar to eculizumab
Amgen Inc.
2020 Phase 3 EUCTR2017-001418-27-PT Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-IE Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-FI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-SI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NO Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NL Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom;
2019 Phase 3 EUCTR2017-001418-27-DE Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-CZ Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001418-27-GB Germany;Italy;Netherlands;Norway;Spain;United Kingdom;
2017 Phase 3 EUCTR2017-001418-27-ES France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;
ABP 959 - proposed biosimilar to eculizumab
Amgen Inc.
2020 Phase 3 EUCTR2017-001418-27-SE Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
ACH-0144471
ACHILLION PHARMACEUTICALS, INC.
2018 Phase 2 EUCTR2016-002652-25-IT Italy;Korea, Republic of;New Zealand;United Kingdom;
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-003829-18-IT Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Achillion Pharmaceuticals, Inc.
2018 Phase 2 EUCTR2017-000665-79-GB Italy;Korea, Republic of;New Zealand;United Kingdom;
2018 Phase 2 EUCTR2016-002652-25-GB Italy;Korea, Republic of;New Zealand;United Kingdom;
Alexion Pharmaceuticals
2018 Phase 2 NCT03472885 United States;
2017 Phase 2 NCT03181633 Italy;Korea, Republic of;New Zealand;
2017 Phase 2 NCT03053102 Italy;Korea, Republic of;New Zealand;United Kingdom;
Alexion Pharmaceuticals Inc.
2021 Phase 3 EUCTR2019-003829-18-PL Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003829-18-NL Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-GB Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-FR Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
ACH-0145228
Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-IT Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003830-17-GB Italy;Korea, Republic of;New Zealand;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-ES Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;
ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
ALN-62643
Alnylam Pharmaceuticals Inc
2016 Phase 2 EUCTR2016-002943-40-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;
ALN-CC5
Alnylam Pharmaceuticals
2015 Phase 1/Phase 2 NCT02352493 Spain;United Kingdom;
Alnylam Pharmaceuticals Inc
2016 Phase 2 EUCTR2016-002943-40-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;
Regeneron Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-005005-17-HU Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
ALXN1102
Alexion Pharmaceuticals
2011 Phase 1 NCT01335165 Czech Republic;Italy;Poland;United Kingdom;United States;
ALXN1103
Alexion Pharmaceuticals
2011 Phase 1 NCT01335165 Czech Republic;Italy;Poland;United Kingdom;United States;
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2017-002370-39-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-IT Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-IT Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals
2018 Phase 3 NCT03406507 France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2015 Phase 1/Phase 2 NCT02598583 Australia;Korea, Republic of;
Alexion Pharmaceuticals Inc.
2020 Phase 4 EUCTR2019-003440-74-GB United Kingdom;
Alexion Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002820-26-NO France;Netherlands;Norway;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002820-26-NL France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002820-26-GB France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-GB Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-ES Germany;Spain;United States;
2017 Phase 3 EUCTR2016-002026-36-DE Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PT Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PL Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-NL Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-FI Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-ES Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-CZ Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
2017 Phase 3 EUCTR2016-002025-11-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-GB Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DK Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2017-002820-26-FR France;Netherlands;United States;
Alexion Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-002370-39-SE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-NL Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-FI Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002370-39-FR Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002674-20-SE Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;
2015 Phase 2 EUCTR2015-002674-20-GB Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002674-20-DE Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2015 - EUCTR2015-002674-20-ES Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;
ALXN2040
Alexion Pharmaceuticals Inc.
2022 Phase 3 EUCTR2019-003829-18-GR Argentina;Brazil;Canada;Colombia;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003829-18-DE Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
ALXN2040 (ACH-0144471)
Alexion Pharmaceuticals Inc.
2018 Phase 2 EUCTR2016-003526-16-GB Italy;United Kingdom;United States;
ALXN2050
Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-IT Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003830-17-GB Italy;Korea, Republic of;New Zealand;United Kingdom;United States;
Alexion Pharmaceuticals
2019 Phase 2 NCT04170023 Canada;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-ES Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;
APL-2
Apellis Pharmaceuticals
2018 Phase 2 EUCTR2017-005140-16-GR Bulgaria;Greece;Poland;Romania;Serbia;
2018 Phase 2 EUCTR2017-005140-16-BG Bulgaria;Greece;Poland;Romania;Serbia;
Apellis Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2019-001106-23-FR Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001106-23-ES Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 NCT04085601 Colombia;Hong Kong;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Singapore;Thailand;
2019 Phase 3 EUCTR2018-004220-11-PL Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand;
2019 Phase 3 EUCTR2017-004268-36-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 NCT03500549 Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-ES Australia;Canada;Japan;Korea, Republic of;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2017-004268-36-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 2 NCT03593200 Bulgaria;Greece;Poland;Romania;Serbia;
2015 Phase 1 NCT02588833 Hong Kong;Malaysia;New Zealand;Thailand;
2015 Phase 1 NCT02264639 United States;
ARO-C3
Arrowhead Pharmaceuticals
2022 Phase 1 NCT05083364 New Zealand;
Allogeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Allogeneic hematopoietic stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
2009 - NCT00856388 United States;
Allogeneic stem cell transplantation
St. Jude Children's Research Hospital
2005 Phase 2 NCT00143559 United States;
Anti-C5 antibody
ALEXION PHARMACEUTICALS INCORPORATED
2006 - EUCTR2005-000043-28-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2005-000043-28-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-IE Ireland;Italy;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-GB Ireland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000646-20-SE Ireland;Italy;Sweden;
ALEXION PHARMACEUTICALS, INC.
- - EUCTR2009-010402-11-Outside-EU/EEA United States;
Anti-thymocyte globulin
Roswell Park Cancer Institute
2009 - NCT00856388 United States;
BCD-148
Biocad
2019 Phase 3 NCT04060264 Russian Federation;
BCX9930
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116774 France;Hungary;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 NCT04702568 Austria;South Africa;United Kingdom;
2020 Phase 1/Phase 2 NCT04330534 Austria;South Africa;United Kingdom;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004403-14-LT Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Lithuania;Serbia;South Africa;Turkey;United States;
2021 Phase 2 EUCTR2020-004403-14-ES Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Lithuania;Serbia;South Africa;Spain;Turkey;United States;
BCX9930 hydrochloride
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004403-14-IT Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Italy;Lithuania;Serbia;South Africa;Spain;Turkey;United States;
2020 Phase 2 EUCTR2020-000501-93-IT Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 2 EUCTR2020-000501-93-GB European Union;South Africa;United Kingdom;
2020 Phase 2 EUCTR2020-000501-93-DK Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
2020 Phase 2 EUCTR2020-000501-93-AT Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
BCX9930 monotherapy
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116787 Malaysia;South Africa;Spain;Taiwan;United States;
BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
BEXSERO – Sospensione iniettabile – Siringa preriempita
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
Bryostatin 1
National Cancer Institute (NCI)
2001 Phase 1 NCT00012376 United States;
C5 Inhibitor
Alexion Pharmaceuticals
2020 Phase 3 NCT04469465 Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Thailand;United Kingdom;United States;
C5 inh MAb, SKY59, RO/CH7092230
F. HOFFMANN - LA ROCHE LTD.
2017 Phase 1;Phase 2 EUCTR2016-002128-10-IT Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-HU Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-FR France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2016 Phase 1;Phase 2 EUCTR2016-002128-10-NL Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom;
COVERSIN
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Campath, Chemo and/or TBI Allo SCT
David Rizzieri, MD
1999 Phase 2 NCT00004143 United States;
Cemdisiran
Regeneron Pharmaceuticals
2022 Phase 3 NCT05133531 United States;
2021 Phase 2 NCT04888507 United Kingdom;
2021 Phase 2 NCT04811716 Hungary;Korea, Republic of;
Crovalimab
CHUGAI PHARMACEUTICAL CO., LTD.
2017 Phase 1-2 JPRN-JapicCTI-173517 Japan, Asia except Japan, Europe;
Chugai Pharmaceutical Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205430 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2020 Phase 3 JPRN-JapicCTI-205425 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-000597-26-IT Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Hoffmann-La Roche
2021 Phase 3 NCT04654468 China;
2020 Phase 3 NCT04434092 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04432584 Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 1/Phase 2 NCT03157635 France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
Cyclophosphamide
National Heart, Lung, and Blood Institute (NHLBI)
2019 Phase 2 NCT03520647 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1996 Phase 2 NCT00004464 United States;
Cyclosporine
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
Cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Memorial Sloan Kettering Cancer Center
2001 Phase 2 NCT00587054 United States;
Danicopan
Alexion Pharmaceuticals
2020 Phase 3 NCT04469465 Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Thailand;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2018 Phase 2 EUCTR2016-003526-16-GB Italy;United Kingdom;United States;
Kamata Takeo
2021 Phase 3 JPRN-jRCT2021210014 America;Japan;
Danicopan (ALXN2040)
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-003829-18-IT Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2021 Phase 3 EUCTR2019-003829-18-PL Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003829-18-NL Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-GB Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-FR Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Eculizumab
ALEXION PHARMACEUTICALS INC
2005 - EUCTR2005-000043-28-IT Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-IT Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-000646-20-IT Ireland;Italy;Sweden;
ALEXION PHARMACEUTICALS INCORPORATED
2006 - EUCTR2005-000043-28-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2005-000043-28-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-IE Ireland;Italy;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-GB Ireland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000646-20-SE Ireland;Italy;Sweden;
Alexion Pharmaceuticals
2021 Phase 4 NCT04320602 United Kingdom;
2018 Phase 2 NCT03472885 United States;
2017 Phase 3 NCT03056040 Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 NCT02946463 Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2009 Phase 4 NCT00867932 United States;
2008 Phase 2 NCT01194804 -
2007 Phase 3 NCT00438789 United States;
2007 Phase 2 NCT01192399 -
2005 Phase 3 NCT00122317 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2004 Phase 3 NCT00122330 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States;
2004 Phase 3 NCT00122304 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Amgen
2019 Phase 3 NCT03818607 Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116774 France;Hungary;Spain;Taiwan;United Kingdom;United States;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Chugai Pharmaceutical Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205430 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2020 Phase 3 JPRN-JapicCTI-205425 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-000597-26-IT Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-IT Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Hoffmann-La Roche
2020 Phase 3 NCT04434092 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04432584 Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
Jonsson Comprehensive Cancer Center
2004 Phase 3 NCT00112983 United States;
National Heart, Lung, and Blood Institute (NHLBI)
2005 Phase 3 NCT00130000 United States;
2004 Phase 3 NCT00098280 United States;
Novartis Pharmaceuticals
2021 Phase 3 NCT04558918 Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Radboud University
2021 - NCT04079257 Netherlands;
Suzuki Kazuyuki
2021 Phase 3 JPRN-jRCT2051200132 Japan;Netherlands;
Elizaria®
AO GENERIUM
2019 - NCT04671810 Russian Federation;
2017 Phase 3 NCT04463056 Russian Federation;
Fc- and CDR-modified humanised monoclonal antibody against C5
Alexion Pharmaceuticals Incorporated
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-GB Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-ES Germany;Spain;United States;
2017 Phase 3 EUCTR2016-002026-36-DE Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PT Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PL Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-NL Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-FI Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-ES Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-CZ Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
2017 Phase 3 EUCTR2016-002025-11-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-GB Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DK Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-002370-39-SE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-NL Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-FI Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002370-39-FR Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Filgrastim
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1996 Phase 2 NCT00004464 United States;
Fludarabine Phosphate
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Fludarabine phosphate
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
2009 - NCT00856388 United States;
G-CSF
Tianjin Medical University General Hospital
2014 - ChiCTR-ONC-13003994 China;
Gelatin
Suzuki Kazuyuki
2021 Phase 3 JPRN-jRCT2021210059 Italy;Japan;Republic of Korea;Taiwan;
H5G1.1-mAb
ALEXION PHARMACEUTICALS INC
2005 - EUCTR2005-000043-28-IT Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
HAEMOPHILUS INFLUENZAE
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
Human monoclonal antibody directed against complement 5 protein
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Iptacopan
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2021 Phase 3 EUCTR2020-004385-19-ES Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States;
Novartis Pharma AG
2022 Phase 3 EUCTR2020-004385-19-NL Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-LT Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-FR Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-FR China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003172-41-CZ China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Novartis Pharmaceuticals
2021 Phase 3 NCT04747613 France;Italy;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;
Iptacopan (LNP023)
Novartis Pharmaceuticals
2021 Phase 3 NCT04820530 China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;
Iron Dextran
Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
2014 - ChiCTR-TRC-14004219 China;
Iron sucrose
Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
2014 - ChiCTR-TRC-14004219 China;
L04AA25
ALEXION PHARMACEUTICALS INCORPORATED
2005 - EUCTR2005-000043-28-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
LFG316
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Novartis Pharmaceuticals
2015 Phase 2 NCT02534909 Czech Republic;Czechia;Japan;Lithuania;Moldova, Republic of;
LNP023
Novartis Pharmaceuticals
2021 Phase 3 NCT04558918 Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 NCT03896152 Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan;
2018 Phase 2 NCT03439839 France;Germany;Italy;
LNP023 HYDROCHLORIDE SALT
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Levamisole+cyclosporin A+Glucocorticoids
Institute of Hematology & Blood Diseases Hospital
2013 Phase 2 NCT01760096 China;
2012 Phase 2 NCT01642979 China;
MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
MENVEO – Polvere e soluzione per soluzione iniettabile
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Melphalan
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
2009 - NCT00856388 United States;
Methotrexate
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Methylprednisolone
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039675 Chinese;
Miltenyi Biotec CliniMACS
St. Jude Children's Research Hospital
2003 Phase 2 NCT00145613 United States;
Miltenyi CliniMACS
St. Jude Children's Research Hospital
2005 Phase 2 NCT00143559 United States;
Mycophenolate mofetil
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
No
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Pegcetacoplan
Apellis Pharmaceuticals, Inc.
2021 Phase 2 NCT04901936 United States;
2021 - NCT04729062 United States;
2020 Phase 3 EUCTR2019-001106-23-FR Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001106-23-ES Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001106-23-BG Australia;Bulgaria;Canada;France;Germany;Hong Kong;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004220-11-PL Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand;
2018 Phase 3 NCT03531255 Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Singapore;Spain;Thailand;United Kingdom;United States;
- Phase 2 EUCTR2020-001350-21-CZ Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States;
Pegcetacoplan (APL-2)
Apellis Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2019-001106-23-GB Australia;Bulgaria;Canada;France;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-001106-23-DE Australia;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Peripheral blood stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Pozelimab
Regeneron Pharmaceuticals
2022 Phase 3 NCT05133531 United States;
2021 Phase 2 NCT04888507 United Kingdom;
2021 Phase 2 NCT04811716 Hungary;Korea, Republic of;
Regeneron Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-005005-17-HU Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
RA101495
Ra Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2018-003956-19-FI Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-FI Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
RA101495 sodium
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003522-16-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-FI Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
REGN3918
REGENERON PHARMACEUTICALS, INC.
2019 Phase 3 EUCTR2019-000130-20-IT Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-IT Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
Regeneron Pharmaceuticals
2019 Phase 3 NCT04162470 Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
2019 Phase 2 NCT03946748 Hong Kong;Hungary;Korea, Republic of;Malaysia;United Kingdom;
Regeneron Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-005005-17-HU Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
2020 Phase 3 EUCTR2019-000130-20-NL Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000130-20-HU Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000130-20-GB Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000130-20-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2018-002734-20-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-NL Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-HU Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-GB Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
RO7112689
CHUGAI PHARMACEUTICAL CO., LTD.
2017 Phase 1-2 JPRN-JapicCTI-173517 Japan, Asia except Japan, Europe;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-000597-26-IT Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-IT Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-FR Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-HU Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-PT Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-CZ Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-PL Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-GR Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RO7112689/F01
F. HOFFMANN - LA ROCHE LTD.
2017 Phase 1;Phase 2 EUCTR2016-002128-10-IT Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-HU Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-FR France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2016 Phase 1;Phase 2 EUCTR2016-002128-10-NL Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom;
RO7112689/F03-01
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-PL Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-DE Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-EE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-BE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-DE Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-SE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-IE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RO7112689/F03-03
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
RO7112689/F03-10
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-PL Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-DE Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2019-004931-21-IE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-EE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-BE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-DE Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-SE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-IE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RVA576
AKARI Therapeutics
2018 Phase 3 NCT03588026 Kazakhstan;Lithuania;Sri Lanka;
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2018 Phase 3 EUCTR2016-004129-18-NL Argentina;Lithuania;Netherlands;Poland;United Kingdom;
2017 Phase 3 EUCTR2016-004129-18-GB Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2016 Phase 2 EUCTR2016-002067-33-GB United Kingdom;
Akari Therapeutics Plc.
2018 Phase 3 EUCTR2017-003847-39-LT Ecuador;Kazakhstan;Lithuania;Peru;Romania;Sri Lanka;Turkey;
Volution Immuno Pharmaceuticals (UK) Ltd
2016 Phase 2 EUCTR2015-003778-34-NL Netherlands;
RVA576 (COVERSIN)
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
RVA576 (Coversin)
AKARI Therapeutics
2017 Phase 3 NCT03829449 Poland;
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Ravulizumab
ALEXION PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2017-002370-39-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals
2022 - NCT05274633 -
2021 Phase 4 NCT04320602 United Kingdom;
2017 Phase 3 NCT03056040 Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 NCT02946463 Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 2 NCT02605993 Canada;France;Germany;Korea, Republic of;Spain;Sweden;Taiwan;United Kingdom;
Alexion Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002820-26-NL France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002820-26-GB France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
Alexion Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-002370-39-SE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-NL Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-FI Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002370-39-FR Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116774 France;Hungary;Spain;Taiwan;United Kingdom;United States;
Novartis Pharmaceuticals
2021 Phase 3 NCT04558918 Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Regeneron Pharmaceuticals
2022 Phase 3 NCT05133531 United States;
Suzuki Kazuyuki
2021 Phase 3 JPRN-jRCT2051200132 Japan;Netherlands;
Reduced Intensity Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Reduced Toxicity Ablative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
SB12 (proposed eculizumab biosimilar)
Samsung Bioepis Co., Ltd.
2019 Phase 3 NCT04058158 India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine;
SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002026-36-IT Germany;Italy;Netherlands;Spain;United Kingdom;United States;
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
SOLIRIS® (eculizumab) injection, for intravenous use
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-PT Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Sargramostim
National Cancer Institute (NCI)
2001 Phase 1 NCT00012376 United States;
Sirolimus
Peking Union Medical College Hospital
2019 Phase 4 NCT03866681 China;
Solaris
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Soliris
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002025-11-IT Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-GB Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-ES Germany;Spain;United States;
2017 Phase 3 EUCTR2016-002026-36-DE Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PT Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PL Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-NL Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-FI Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-ES Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-CZ Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
2017 Phase 3 EUCTR2016-002025-11-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-GB Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DK Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Amgen Inc.
2020 Phase 3 EUCTR2017-001418-27-SE Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-PT Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-IE Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-FI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-SI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NO Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NL Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom;
2019 Phase 3 EUCTR2017-001418-27-DE Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-CZ Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001418-27-GB Germany;Italy;Netherlands;Norway;Spain;United Kingdom;
2017 Phase 3 EUCTR2017-001418-27-ES France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;
Apellis Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-004268-36-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 NCT03500549 Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-ES Australia;Canada;Japan;Korea, Republic of;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2017-004268-36-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Biocad
2019 Phase 3 NCT04060264 Russian Federation;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2019-004931-21-IT Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-FR Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-PL Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-HU Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-DE Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2019-004931-21-IE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-EE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-BE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-DE Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-SE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-IE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
NOVARTIS PHARMA AG
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-CZ Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-HU Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-FR Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Soliris (eculizumab)
Samsung Bioepis Co., Ltd.
2019 Phase 3 NCT04058158 India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine;
Soliris 300
Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
2019 Phase 4 EUCTR2019-001453-10-ES Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
Soliris 300 mg concentrate for solution for infusion
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Soliris 300mg/30ml
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Soliris®
AO GENERIUM
2017 Phase 3 NCT04463056 Russian Federation;
Stem Cell Transplantation
St. Jude Children's Research Hospital
2003 Phase 2 NCT00145613 United States;
Sterile Normal Saline ( NaCl)
Alnylam Pharmaceuticals
2015 Phase 1/Phase 2 NCT02352493 Spain;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003522-16-FI Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003522-16-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-FI Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker
Ra Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2018-003956-19-FI Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
Systematic chemotherapy and antibodies
St. Jude Children's Research Hospital
2005 Phase 2 NCT00143559 United States;
Systemic chemotherapy and antibodies
St. Jude Children's Research Hospital
2003 Phase 2 NCT00145613 United States;
Tacrolimus
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Treosulfan
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Tretinoin
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039675 Chinese;
ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Ultomiris
Alexion Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002820-26-NL France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002820-26-GB France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-CZ Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-HU Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Ultomiris 300mg/30ml
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
VACCINO PNEUMOCOCCICO
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VARI
ALEXION PHARMACEUTICALS INC
2004 - EUCTR2004-000646-20-IT Ireland;Italy;Sweden;
Zilucoplan
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-FI Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
Zilucoplan (RA101495)
Ra Pharmaceuticals
2017 Phase 2 NCT03225287 Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 NCT03078582 Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 NCT03030183 United States;
LNP023 HYDROCHLORIDE SALT
Novartis Farmacéutica, S.A.
2021 Phase 3 EUCTR2020-004385-19-ES Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States;
Novartis Pharma AG
2022 Phase 3 EUCTR2020-004385-19-NL Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-LT Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-FR Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-FR China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003172-41-CZ China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004665-40-CZ Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-HU Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-FR Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-000888-33-FR France;Germany;Italy;
2018 Phase 2 EUCTR2017-000888-33-DE France;Germany;Italy;
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Amgen
2019 Phase 3 NCT03818607 Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
ABP 959 - biosimilar to eculizumab
Amgen Inc.
2020 Phase 3 EUCTR2017-001418-27-PT Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-IE Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-FI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-SI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NO Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NL Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom;
2019 Phase 3 EUCTR2017-001418-27-DE Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-CZ Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001418-27-GB Germany;Italy;Netherlands;Norway;Spain;United Kingdom;
2017 Phase 3 EUCTR2017-001418-27-ES France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;
ABP 959 - proposed biosimilar to eculizumab
Amgen Inc.
2020 Phase 3 EUCTR2017-001418-27-SE Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
ACH-0144471
ACHILLION PHARMACEUTICALS, INC.
2018 Phase 2 EUCTR2016-002652-25-IT Italy;Korea, Republic of;New Zealand;United Kingdom;
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-003829-18-IT Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Achillion Pharmaceuticals, Inc.
2018 Phase 2 EUCTR2017-000665-79-GB Italy;Korea, Republic of;New Zealand;United Kingdom;
2018 Phase 2 EUCTR2016-002652-25-GB Italy;Korea, Republic of;New Zealand;United Kingdom;
Alexion Pharmaceuticals
2018 Phase 2 NCT03472885 United States;
2017 Phase 2 NCT03181633 Italy;Korea, Republic of;New Zealand;
2017 Phase 2 NCT03053102 Italy;Korea, Republic of;New Zealand;United Kingdom;
Alexion Pharmaceuticals Inc.
2021 Phase 3 EUCTR2019-003829-18-PL Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003829-18-NL Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-GB Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-FR Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
ACH-0145228
Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-IT Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003830-17-GB Italy;Korea, Republic of;New Zealand;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-ES Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;
ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
ALN-62643
Alnylam Pharmaceuticals Inc
2016 Phase 2 EUCTR2016-002943-40-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;
ALN-CC5
Alnylam Pharmaceuticals
2015 Phase 1/Phase 2 NCT02352493 Spain;United Kingdom;
Alnylam Pharmaceuticals Inc
2016 Phase 2 EUCTR2016-002943-40-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;
Regeneron Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-005005-17-HU Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
ALXN1102
Alexion Pharmaceuticals
2011 Phase 1 NCT01335165 Czech Republic;Italy;Poland;United Kingdom;United States;
ALXN1103
Alexion Pharmaceuticals
2011 Phase 1 NCT01335165 Czech Republic;Italy;Poland;United Kingdom;United States;
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2017-002370-39-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-IT Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-IT Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals
2018 Phase 3 NCT03406507 France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2015 Phase 1/Phase 2 NCT02598583 Australia;Korea, Republic of;
Alexion Pharmaceuticals Inc.
2020 Phase 4 EUCTR2019-003440-74-GB United Kingdom;
Alexion Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002820-26-NO France;Netherlands;Norway;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002820-26-NL France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002820-26-GB France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-GB Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-ES Germany;Spain;United States;
2017 Phase 3 EUCTR2016-002026-36-DE Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PT Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PL Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-NL Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-FI Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-ES Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-CZ Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
2017 Phase 3 EUCTR2016-002025-11-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-GB Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DK Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2017-002820-26-FR France;Netherlands;United States;
Alexion Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-002370-39-SE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-NL Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-FI Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002370-39-FR Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002674-20-SE Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;
2015 Phase 2 EUCTR2015-002674-20-GB Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002674-20-DE Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2015 - EUCTR2015-002674-20-ES Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;
ALXN2040
Alexion Pharmaceuticals Inc.
2022 Phase 3 EUCTR2019-003829-18-GR Argentina;Brazil;Canada;Colombia;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003829-18-DE Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
ALXN2040 (ACH-0144471)
Alexion Pharmaceuticals Inc.
2018 Phase 2 EUCTR2016-003526-16-GB Italy;United Kingdom;United States;
ALXN2050
Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-IT Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003830-17-GB Italy;Korea, Republic of;New Zealand;United Kingdom;United States;
Alexion Pharmaceuticals
2019 Phase 2 NCT04170023 Canada;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2021 Phase 2 EUCTR2019-003830-17-ES Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;
APL-2
Apellis Pharmaceuticals
2018 Phase 2 EUCTR2017-005140-16-GR Bulgaria;Greece;Poland;Romania;Serbia;
2018 Phase 2 EUCTR2017-005140-16-BG Bulgaria;Greece;Poland;Romania;Serbia;
Apellis Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2019-001106-23-FR Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001106-23-ES Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 NCT04085601 Colombia;Hong Kong;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Singapore;Thailand;
2019 Phase 3 EUCTR2018-004220-11-PL Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand;
2019 Phase 3 EUCTR2017-004268-36-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 NCT03500549 Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-ES Australia;Canada;Japan;Korea, Republic of;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2017-004268-36-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 2 NCT03593200 Bulgaria;Greece;Poland;Romania;Serbia;
2015 Phase 1 NCT02588833 Hong Kong;Malaysia;New Zealand;Thailand;
2015 Phase 1 NCT02264639 United States;
ARO-C3
Arrowhead Pharmaceuticals
2022 Phase 1 NCT05083364 New Zealand;
Allogeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Allogeneic hematopoietic stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
2009 - NCT00856388 United States;
Allogeneic stem cell transplantation
St. Jude Children's Research Hospital
2005 Phase 2 NCT00143559 United States;
Anti-C5 antibody
ALEXION PHARMACEUTICALS INCORPORATED
2006 - EUCTR2005-000043-28-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2005-000043-28-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-IE Ireland;Italy;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-GB Ireland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000646-20-SE Ireland;Italy;Sweden;
ALEXION PHARMACEUTICALS, INC.
- - EUCTR2009-010402-11-Outside-EU/EEA United States;
Anti-thymocyte globulin
Roswell Park Cancer Institute
2009 - NCT00856388 United States;
BCD-148
Biocad
2019 Phase 3 NCT04060264 Russian Federation;
BCX9930
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116774 France;Hungary;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 NCT04702568 Austria;South Africa;United Kingdom;
2020 Phase 1/Phase 2 NCT04330534 Austria;South Africa;United Kingdom;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004403-14-LT Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Lithuania;Serbia;South Africa;Turkey;United States;
2021 Phase 2 EUCTR2020-004403-14-ES Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Lithuania;Serbia;South Africa;Spain;Turkey;United States;
BCX9930 hydrochloride
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004403-14-IT Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Italy;Lithuania;Serbia;South Africa;Spain;Turkey;United States;
2020 Phase 2 EUCTR2020-000501-93-IT Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 2 EUCTR2020-000501-93-GB European Union;South Africa;United Kingdom;
2020 Phase 2 EUCTR2020-000501-93-DK Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
2020 Phase 2 EUCTR2020-000501-93-AT Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
BCX9930 monotherapy
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116787 Malaysia;South Africa;Spain;Taiwan;United States;
BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
BEXSERO – Sospensione iniettabile – Siringa preriempita
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
Bryostatin 1
National Cancer Institute (NCI)
2001 Phase 1 NCT00012376 United States;
C5 Inhibitor
Alexion Pharmaceuticals
2020 Phase 3 NCT04469465 Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Thailand;United Kingdom;United States;
C5 inh MAb, SKY59, RO/CH7092230
F. HOFFMANN - LA ROCHE LTD.
2017 Phase 1;Phase 2 EUCTR2016-002128-10-IT Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-HU Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-FR France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2016 Phase 1;Phase 2 EUCTR2016-002128-10-NL Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom;
COVERSIN
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Campath, Chemo and/or TBI Allo SCT
David Rizzieri, MD
1999 Phase 2 NCT00004143 United States;
Cemdisiran
Regeneron Pharmaceuticals
2022 Phase 3 NCT05133531 United States;
2021 Phase 2 NCT04888507 United Kingdom;
2021 Phase 2 NCT04811716 Hungary;Korea, Republic of;
Crovalimab
CHUGAI PHARMACEUTICAL CO., LTD.
2017 Phase 1-2 JPRN-JapicCTI-173517 Japan, Asia except Japan, Europe;
Chugai Pharmaceutical Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205430 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2020 Phase 3 JPRN-JapicCTI-205425 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-000597-26-IT Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Hoffmann-La Roche
2021 Phase 3 NCT04654468 China;
2020 Phase 3 NCT04434092 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04432584 Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 1/Phase 2 NCT03157635 France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
Cyclophosphamide
National Heart, Lung, and Blood Institute (NHLBI)
2019 Phase 2 NCT03520647 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1996 Phase 2 NCT00004464 United States;
Cyclosporine
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
Cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Memorial Sloan Kettering Cancer Center
2001 Phase 2 NCT00587054 United States;
Danicopan
Alexion Pharmaceuticals
2020 Phase 3 NCT04469465 Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Thailand;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2018 Phase 2 EUCTR2016-003526-16-GB Italy;United Kingdom;United States;
Kamata Takeo
2021 Phase 3 JPRN-jRCT2021210014 America;Japan;
Danicopan (ALXN2040)
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-003829-18-IT Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Alexion Pharmaceuticals Inc.
2021 Phase 3 EUCTR2019-003829-18-PL Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003829-18-NL Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-GB Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003829-18-FR Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Eculizumab
ALEXION PHARMACEUTICALS INC
2005 - EUCTR2005-000043-28-IT Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-IT Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-000646-20-IT Ireland;Italy;Sweden;
ALEXION PHARMACEUTICALS INCORPORATED
2006 - EUCTR2005-000043-28-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2005-000043-28-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-GB Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002795-42-ES Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-IE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-000043-28-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-SE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002795-42-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-IE Ireland;Italy;Sweden;United Kingdom;
2004 Phase 3 EUCTR2004-000646-20-GB Ireland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000646-20-SE Ireland;Italy;Sweden;
Alexion Pharmaceuticals
2021 Phase 4 NCT04320602 United Kingdom;
2018 Phase 2 NCT03472885 United States;
2017 Phase 3 NCT03056040 Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 NCT02946463 Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2009 Phase 4 NCT00867932 United States;
2008 Phase 2 NCT01194804 -
2007 Phase 3 NCT00438789 United States;
2007 Phase 2 NCT01192399 -
2005 Phase 3 NCT00122317 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2004 Phase 3 NCT00122330 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States;
2004 Phase 3 NCT00122304 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Amgen
2019 Phase 3 NCT03818607 Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116774 France;Hungary;Spain;Taiwan;United Kingdom;United States;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Chugai Pharmaceutical Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205430 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2020 Phase 3 JPRN-JapicCTI-205425 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-000597-26-IT Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-IT Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Hoffmann-La Roche
2020 Phase 3 NCT04434092 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04432584 Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
Jonsson Comprehensive Cancer Center
2004 Phase 3 NCT00112983 United States;
National Heart, Lung, and Blood Institute (NHLBI)
2005 Phase 3 NCT00130000 United States;
2004 Phase 3 NCT00098280 United States;
Novartis Pharmaceuticals
2021 Phase 3 NCT04558918 Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Radboud University
2021 - NCT04079257 Netherlands;
Suzuki Kazuyuki
2021 Phase 3 JPRN-jRCT2051200132 Japan;Netherlands;
Elizaria®
AO GENERIUM
2019 - NCT04671810 Russian Federation;
2017 Phase 3 NCT04463056 Russian Federation;
Fc- and CDR-modified humanised monoclonal antibody against C5
Alexion Pharmaceuticals Incorporated
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-GB Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-ES Germany;Spain;United States;
2017 Phase 3 EUCTR2016-002026-36-DE Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PT Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PL Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-NL Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-FI Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-ES Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-CZ Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
2017 Phase 3 EUCTR2016-002025-11-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-GB Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DK Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-002370-39-SE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-NL Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-FI Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002370-39-FR Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Filgrastim
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1996 Phase 2 NCT00004464 United States;
Fludarabine Phosphate
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Fludarabine phosphate
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
2009 - NCT00856388 United States;
G-CSF
Tianjin Medical University General Hospital
2014 - ChiCTR-ONC-13003994 China;
Gelatin
Suzuki Kazuyuki
2021 Phase 3 JPRN-jRCT2021210059 Italy;Japan;Republic of Korea;Taiwan;
H5G1.1-mAb
ALEXION PHARMACEUTICALS INC
2005 - EUCTR2005-000043-28-IT Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
HAEMOPHILUS INFLUENZAE
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
Human monoclonal antibody directed against complement 5 protein
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Iptacopan
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2021 Phase 3 EUCTR2020-004385-19-ES Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States;
Novartis Pharma AG
2022 Phase 3 EUCTR2020-004385-19-NL Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-LT Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-FR Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-FR China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003172-41-CZ China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Novartis Pharmaceuticals
2021 Phase 3 NCT04747613 France;Italy;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;
Iptacopan (LNP023)
Novartis Pharmaceuticals
2021 Phase 3 NCT04820530 China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;
Iron Dextran
Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
2014 - ChiCTR-TRC-14004219 China;
Iron sucrose
Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
2014 - ChiCTR-TRC-14004219 China;
L04AA25
ALEXION PHARMACEUTICALS INCORPORATED
2005 - EUCTR2005-000043-28-DE Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
LFG316
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Novartis Pharmaceuticals
2015 Phase 2 NCT02534909 Czech Republic;Czechia;Japan;Lithuania;Moldova, Republic of;
LNP023
Novartis Pharmaceuticals
2021 Phase 3 NCT04558918 Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 NCT03896152 Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan;
2018 Phase 2 NCT03439839 France;Germany;Italy;
LNP023 HYDROCHLORIDE SALT
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Levamisole+cyclosporin A+Glucocorticoids
Institute of Hematology & Blood Diseases Hospital
2013 Phase 2 NCT01760096 China;
2012 Phase 2 NCT01642979 China;
MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
MENVEO – Polvere e soluzione per soluzione iniettabile
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Melphalan
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
2009 - NCT00856388 United States;
Methotrexate
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Methylprednisolone
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039675 Chinese;
Miltenyi Biotec CliniMACS
St. Jude Children's Research Hospital
2003 Phase 2 NCT00145613 United States;
Miltenyi CliniMACS
St. Jude Children's Research Hospital
2005 Phase 2 NCT00143559 United States;
Mycophenolate mofetil
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
No
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Pegcetacoplan
Apellis Pharmaceuticals, Inc.
2021 Phase 2 NCT04901936 United States;
2021 - NCT04729062 United States;
2020 Phase 3 EUCTR2019-001106-23-FR Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001106-23-ES Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001106-23-BG Australia;Bulgaria;Canada;France;Germany;Hong Kong;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004220-11-PL Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand;
2018 Phase 3 NCT03531255 Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Singapore;Spain;Thailand;United Kingdom;United States;
- Phase 2 EUCTR2020-001350-21-CZ Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States;
Pegcetacoplan (APL-2)
Apellis Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2019-001106-23-GB Australia;Bulgaria;Canada;France;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-001106-23-DE Australia;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00397813 Denmark;Germany;Italy;United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Peripheral blood stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Pozelimab
Regeneron Pharmaceuticals
2022 Phase 3 NCT05133531 United States;
2021 Phase 2 NCT04888507 United Kingdom;
2021 Phase 2 NCT04811716 Hungary;Korea, Republic of;
Regeneron Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-005005-17-HU Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
RA101495
Ra Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2018-003956-19-FI Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-FI Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
RA101495 sodium
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003522-16-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-FI Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
REGN3918
REGENERON PHARMACEUTICALS, INC.
2019 Phase 3 EUCTR2019-000130-20-IT Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-IT Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
Regeneron Pharmaceuticals
2019 Phase 3 NCT04162470 Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
2019 Phase 2 NCT03946748 Hong Kong;Hungary;Korea, Republic of;Malaysia;United Kingdom;
Regeneron Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-005005-17-HU Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
2020 Phase 3 EUCTR2019-000130-20-NL Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000130-20-HU Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000130-20-GB Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000130-20-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2018-002734-20-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-NL Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-HU Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002734-20-GB Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
RO7112689
CHUGAI PHARMACEUTICAL CO., LTD.
2017 Phase 1-2 JPRN-JapicCTI-173517 Japan, Asia except Japan, Europe;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-000597-26-IT Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-IT Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-FR Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-HU Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-PT Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-CZ Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-PL Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-GR Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RO7112689/F01
F. HOFFMANN - LA ROCHE LTD.
2017 Phase 1;Phase 2 EUCTR2016-002128-10-IT Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-HU Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-FR France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
2016 Phase 1;Phase 2 EUCTR2016-002128-10-NL Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom;
RO7112689/F03-01
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-PL Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-DE Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-EE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-BE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-DE Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-SE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-IE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RO7112689/F03-03
F. Hoffmann-La Roche Ltd
2017 Phase 1;Phase 2 EUCTR2016-002128-10-DE France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
RO7112689/F03-10
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-PL Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-DE Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2019-004931-21-IE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-EE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-BE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-DE Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-SE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-IE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RVA576
AKARI Therapeutics
2018 Phase 3 NCT03588026 Kazakhstan;Lithuania;Sri Lanka;
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2018 Phase 3 EUCTR2016-004129-18-NL Argentina;Lithuania;Netherlands;Poland;United Kingdom;
2017 Phase 3 EUCTR2016-004129-18-GB Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2016 Phase 2 EUCTR2016-002067-33-GB United Kingdom;
Akari Therapeutics Plc.
2018 Phase 3 EUCTR2017-003847-39-LT Ecuador;Kazakhstan;Lithuania;Peru;Romania;Sri Lanka;Turkey;
Volution Immuno Pharmaceuticals (UK) Ltd
2016 Phase 2 EUCTR2015-003778-34-NL Netherlands;
RVA576 (COVERSIN)
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
RVA576 (Coversin)
AKARI Therapeutics
2017 Phase 3 NCT03829449 Poland;
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Ravulizumab
ALEXION PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2017-002370-39-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals
2022 - NCT05274633 -
2021 Phase 4 NCT04320602 United Kingdom;
2017 Phase 3 NCT03056040 Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 NCT02946463 Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 2 NCT02605993 Canada;France;Germany;Korea, Republic of;Spain;Sweden;Taiwan;United Kingdom;
Alexion Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002820-26-NL France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002820-26-GB France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
Alexion Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-002370-39-SE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-NL Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-FI Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002370-39-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002370-39-FR Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
BioCryst Pharmaceuticals
2021 Phase 2 NCT05116774 France;Hungary;Spain;Taiwan;United Kingdom;United States;
Novartis Pharmaceuticals
2021 Phase 3 NCT04558918 Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Regeneron Pharmaceuticals
2022 Phase 3 NCT05133531 United States;
Suzuki Kazuyuki
2021 Phase 3 JPRN-jRCT2051200132 Japan;Netherlands;
Reduced Intensity Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Reduced Toxicity Ablative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
SB12 (proposed eculizumab biosimilar)
Samsung Bioepis Co., Ltd.
2019 Phase 3 NCT04058158 India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine;
SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002026-36-IT Germany;Italy;Netherlands;Spain;United Kingdom;United States;
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
SOLIRIS® (eculizumab) injection, for intravenous use
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-PT Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Sargramostim
National Cancer Institute (NCI)
2001 Phase 1 NCT00012376 United States;
Sirolimus
Peking Union Medical College Hospital
2019 Phase 4 NCT03866681 China;
Solaris
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Soliris
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002025-11-IT Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-GB Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-ES Germany;Spain;United States;
2017 Phase 3 EUCTR2016-002026-36-DE Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PT Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-PL Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-NL Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-FI Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-ES Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-CZ Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
2017 Phase 3 EUCTR2016-002025-11-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-GB Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DK Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002025-11-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Amgen Inc.
2020 Phase 3 EUCTR2017-001418-27-SE Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-PT Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-IE Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2017-001418-27-FI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-SI Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NO Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-NL Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom;
2019 Phase 3 EUCTR2017-001418-27-DE Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001418-27-CZ Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001418-27-GB Germany;Italy;Netherlands;Norway;Spain;United Kingdom;
2017 Phase 3 EUCTR2017-001418-27-ES France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;
Apellis Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2017-004268-36-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004268-36-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 NCT03500549 Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-ES Australia;Canada;Japan;Korea, Republic of;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2017-004268-36-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004268-36-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Biocad
2019 Phase 3 NCT04060264 Russian Federation;
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2019-004931-21-IT Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-FR Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004931-21-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-PL Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-HU Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004931-21-DE Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2019-004931-21-IE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-000597-26-EE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000597-26-BE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000597-26-DE Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-SE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-000597-26-IE Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
NOVARTIS PHARMA AG
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-CZ Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-HU Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-FR Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Soliris (eculizumab)
Samsung Bioepis Co., Ltd.
2019 Phase 3 NCT04058158 India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine;
Soliris 300
Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
2019 Phase 4 EUCTR2019-001453-10-ES Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
Soliris 300 mg concentrate for solution for infusion
F. Hoffman-La Roche Ltd.
2021 Phase 3 EUCTR2019-004931-21-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Soliris 300mg/30ml
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Soliris®
AO GENERIUM
2017 Phase 3 NCT04463056 Russian Federation;
Stem Cell Transplantation
St. Jude Children's Research Hospital
2003 Phase 2 NCT00145613 United States;
Sterile Normal Saline ( NaCl)
Alnylam Pharmaceuticals
2015 Phase 1/Phase 2 NCT02352493 Spain;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003522-16-FI Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003523-34-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003522-16-HU Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-GB Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 EUCTR2016-003522-16-DK Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-FI Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker
Ra Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2018-003956-19-FI Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
Systematic chemotherapy and antibodies
St. Jude Children's Research Hospital
2005 Phase 2 NCT00143559 United States;
Systemic chemotherapy and antibodies
St. Jude Children's Research Hospital
2003 Phase 2 NCT00145613 United States;
Tacrolimus
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Treosulfan
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Tretinoin
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039675 Chinese;
ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-004438-39-IT Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Ultomiris
Alexion Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002820-26-NL France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002820-26-GB France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002026-36-NL Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-EE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002025-11-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
BioCryst Pharmaceuticals Inc
2021 Phase 2 EUCTR2020-004438-39-HU Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-FR Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004438-39-ES Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-CZ Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-HU Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Ultomiris 300mg/30ml
Novartis Pharma AG
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
VACCINO PNEUMOCOCCICO
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-004385-19-IT Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-IT China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-IT Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VARI
ALEXION PHARMACEUTICALS INC
2004 - EUCTR2004-000646-20-IT Ireland;Italy;Sweden;
Zilucoplan
Ra Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003523-34-FI Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
Zilucoplan (RA101495)
Ra Pharmaceuticals
2017 Phase 2 NCT03225287 Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
2017 Phase 2 NCT03078582 Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
2017 Phase 2 NCT03030183 United States;
LNP023 HYDROCHLORIDE SALT
Novartis Farmacéutica, S.A.
2021 Phase 3 EUCTR2020-004385-19-ES Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States;
Novartis Pharma AG
2022 Phase 3 EUCTR2020-004385-19-NL Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-LT Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-004385-19-FR Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2020-003172-41-FR China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003172-41-CZ China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004665-40-DE Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004665-40-CZ Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-NL Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-HU Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004665-40-FR Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-000888-33-FR France;Germany;Italy;
2018 Phase 2 EUCTR2017-000888-33-DE France;Germany;Italy;
Novartis Pharma Services AG
2015 Phase 2 EUCTR2014-005338-74-LT Czech Republic;Czechia;Japan;Lithuania;
2015 Phase 2 EUCTR2014-005338-74-CZ Czech Republic;Czechia;Japan;Lithuania;